Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Nitric oxide releasing derivatives of paracetamol patented

April 14, 2009

KAI initiates third phase IIa KAI-1678 trial for neuropathic pain

April 9, 2009

IntelGenx and Cary file NDA for antidepressant, CPI-300

April 9, 2009

Amarin's MAA for AMR-101 in Huntington's disease accepted for review

April 9, 2009

Somaxon provides update on NDA for Silenor for insomnia

April 9, 2009

Avineuro commences phase I AVN-101 study for Alzheimer's disease

April 9, 2009

Novel inhibitors of Abeta calcium channel activity confer neuroprotection in vitro

April 9, 2009

Schering-Plough patent discloses novel gamma-secretase modulators for the treatment of AD

April 9, 2009

FDA Advisory Committee provides opinion on Serdolect in schizophrenia

April 8, 2009

Aplenzin extended-release tablets available in the U.S.

April 8, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...